AC Immune’s ACI-7104 Gets FDA Fast Track Designation for Early Parkinson’s Disease
AC Immune’s ACI-7104 receives FDA Fast Track and IND clearance for early Parkinson’s. Phase 2 VacSYn trial can now expand to US sites.
/ 2 items
AC Immune’s ACI-7104 receives FDA Fast Track and IND clearance for early Parkinson’s. Phase 2 VacSYn trial can now expand to US sites.
AC Immune updates Eli Lilly deal to develop pill-based Tau drugs for Alzheimer’s, aiming to stop disease early with promising preclinical results.